{
  "disease_name": "GM2 gangliosidosis, AB variant",
  "orpha_code": "309246",
  "drugs": [
    {
      "name": "PLERIXAFOR ACCORD",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/642317?name=309246&mode=orpha&region=",
      "regulatory_id": "642317",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
        "(Tradename                        - 16/12/2022)",
        "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/642316?name=309246&mode=orpha&region=&status=all",
          "text": "PLERIXAFOR ACCORD",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/29073",
          "text": "ORPHA:29073 Multiple myeloma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/223735",
          "text": "ORPHA:223735 Lymphoma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/642317?name=309246&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Thiotepa Riemser",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/610636?name=309246&mode=orpha&region=",
      "regulatory_id": "610636",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Thiotepa Riemser(Tradename                        - 26/03/2021)",
        "(Tradename                        - 26/03/2021)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/610616?name=309246&mode=orpha&region=&status=all",
          "text": "Thiotepa Riemser",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/610636?name=309246&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "motixafortide",
      "substance_url": "/en/drug/substance/588874?name=309246&mode=orpha&region=&status=all",
      "substance_id": "588874",
      "regulatory_url": "/en/drug/regulatory/661036?name=309246&mode=orpha&region=",
      "regulatory_id": "661036",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "motixafortide(Medicinal product                        - 12/01/2024)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "motixafortide(Medicinal product                        - 12/01/2024)",
        "(Medicinal product                        - 12/01/2024)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/588874?name=309246&mode=orpha&region=&status=all",
          "text": "motixafortide",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/661036?name=309246&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "(2S,3R,4R,5S)-1-[5-(2-fluoro-biphenyl-4-ylmethoxy)-pentyl]-2-hydroxymethyl-piperidine-3,4,5-triol",
      "substance_url": "/en/drug/substance/642434?name=309246&mode=orpha&region=&status=all",
      "substance_id": "642434",
      "regulatory_url": "/en/drug/regulatory/642438?name=309246&mode=orpha&region=",
      "regulatory_id": "642438",
      "orpha_substance_code": "ORPHA:309152",
      "details": [
        "(2S,3R,4R,5S)-1-[5-(2-fluoro-biphenyl-4-ylmethoxy)-pentyl]-2-hydroxymethyl-piperidine-3,4,5-triol(Medicinal product                        - 15/02/2023)Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
        "(2S,3R,4R,5S)-1-[5-(2-fluoro-biphenyl-4-ylmethoxy)-pentyl]-2-hydroxymethyl-piperidine-3,4,5-triol(Medicinal product                        - 15/02/2023)",
        "(Medicinal product                        - 15/02/2023)",
        "Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/642434?name=309246&mode=orpha&region=&status=all",
          "text": "(2S,3R,4R,5S)-1-[5-(2-fluoro-biphenyl-4-ylmethoxy)-pentyl]-2-hydroxymethyl-piperidine-3,4,5-triol",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/309152",
          "text": "ORPHA:309152 GM2 gangliosidosis",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/642438?name=309246&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Adeno-associated viral vector serotype 9 containing the human HEXA and HEXB genes",
      "substance_url": "/en/drug/substance/627916?name=309246&mode=orpha&region=&status=all",
      "substance_id": "627916",
      "regulatory_url": "/en/drug/regulatory/627917?name=309246&mode=orpha&region=",
      "regulatory_id": "627917",
      "orpha_substance_code": "ORPHA:309152",
      "details": [
        "Adeno-associated viral vector serotype 9 containing the human HEXA and HEXB genes(Medicinal product                        - 20/08/2021)Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
        "Adeno-associated viral vector serotype 9 containing the human HEXA and HEXB genes(Medicinal product                        - 20/08/2021)",
        "(Medicinal product                        - 20/08/2021)",
        "Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/627916?name=309246&mode=orpha&region=&status=all",
          "text": "Adeno-associated viral vector serotype 9 containing the human HEXA and HEXB genes",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/309152",
          "text": "ORPHA:309152 GM2 gangliosidosis",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/627917?name=309246&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Venglustat",
      "substance_url": "/en/drug/substance/406512?name=309246&mode=orpha&region=&status=all",
      "substance_id": "406512",
      "regulatory_url": "/en/drug/regulatory/604849?name=309246&mode=orpha&region=",
      "regulatory_id": "604849",
      "orpha_substance_code": "ORPHA:309152",
      "details": [
        "Venglustat(Medicinal product                        - 21/08/2020)Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
        "Venglustat(Medicinal product                        - 21/08/2020)",
        "(Medicinal product                        - 21/08/2020)",
        "Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/406512?name=309246&mode=orpha&region=&status=all",
          "text": "Venglustat",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/309152",
          "text": "ORPHA:309152 GM2 gangliosidosis",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/604849?name=309246&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
      "substance_url": "/en/drug/substance/589233?name=309246&mode=orpha&region=&status=all",
      "substance_id": "589233",
      "regulatory_url": "/en/drug/regulatory/589234?name=309246&mode=orpha&region=",
      "regulatory_id": "589234",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)",
        "(Medicinal product                        - 20/04/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589233?name=309246&mode=orpha&region=&status=all",
          "text": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589234?name=309246&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
      "substance_url": "/en/drug/substance/589056?name=309246&mode=orpha&region=&status=all",
      "substance_id": "589056",
      "regulatory_url": "/en/drug/regulatory/589057?name=309246&mode=orpha&region=",
      "regulatory_id": "589057",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)",
        "(Medicinal product                        - 24/03/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589056?name=309246&mode=orpha&region=&status=all",
          "text": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589057?name=309246&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Sinbaglustat",
      "substance_url": "/en/drug/substance/572537?name=309246&mode=orpha&region=&status=all",
      "substance_id": "572537",
      "regulatory_url": "/en/drug/regulatory/572539?name=309246&mode=orpha&region=",
      "regulatory_id": "572539",
      "orpha_substance_code": "ORPHA:309152",
      "details": [
        "Sinbaglustat(Medicinal product                        - 13/11/2019)Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
        "Sinbaglustat(Medicinal product                        - 13/11/2019)",
        "(Medicinal product                        - 13/11/2019)",
        "Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/572537?name=309246&mode=orpha&region=&status=all",
          "text": "Sinbaglustat",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/309152",
          "text": "ORPHA:309152 GM2 gangliosidosis",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/572539?name=309246&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Recombinant adeno-associated viral vector serotype 2/1 encoding human beta-hexosaminidase alpha and beta subunits",
      "substance_url": "/en/drug/substance/510739?name=309246&mode=orpha&region=&status=all",
      "substance_id": "510739",
      "regulatory_url": "/en/drug/regulatory/635786?name=309246&mode=orpha&region=",
      "regulatory_id": "635786",
      "orpha_substance_code": "ORPHA:309152",
      "details": [
        "Recombinant adeno-associated viral vector serotype 2/1 encoding human beta-hexosaminidase alpha and beta subunits(Medicinal product                        - 17/01/2018)Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
        "Recombinant adeno-associated viral vector serotype 2/1 encoding human beta-hexosaminidase alpha and beta subunits(Medicinal product                        - 17/01/2018)",
        "(Medicinal product                        - 17/01/2018)",
        "Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/510739?name=309246&mode=orpha&region=&status=all",
          "text": "Recombinant adeno-associated viral vector serotype 2/1 encoding human beta-hexosaminidase alpha and beta subunits",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/309152",
          "text": "ORPHA:309152 GM2 gangliosidosis",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/635786?name=309246&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Acetylleucine",
      "substance_url": "/en/drug/substance/479413?name=309246&mode=orpha&region=&status=all",
      "substance_id": "479413",
      "regulatory_url": "/en/drug/regulatory/500691?name=309246&mode=orpha&region=",
      "regulatory_id": "500691",
      "orpha_substance_code": "ORPHA:309152",
      "details": [
        "Acetylleucine(Medicinal product                        - 12/12/2017)Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
        "Acetylleucine(Medicinal product                        - 12/12/2017)",
        "(Medicinal product                        - 12/12/2017)",
        "Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/479413?name=309246&mode=orpha&region=&status=all",
          "text": "Acetylleucine",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/309152",
          "text": "ORPHA:309152 GM2 gangliosidosis",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/500691?name=309246&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US",
        "EU"
      ]
    },
    {
      "name": "Burixafor",
      "substance_url": "/en/drug/substance/689505?name=309246&mode=orpha&region=&status=all",
      "substance_id": "689505",
      "regulatory_url": "/en/drug/regulatory/689915?name=309246&mode=orpha&region=",
      "regulatory_id": "689915",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Burixafor(Medicinal product                        - 22/10/2024)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Burixafor(Medicinal product                        - 22/10/2024)",
        "(Medicinal product                        - 22/10/2024)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/689505?name=309246&mode=orpha&region=&status=all",
          "text": "Burixafor",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/689915?name=309246&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=309246&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641081?name=309246&mode=orpha&region=",
      "regulatory_id": "641081",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=309246&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641081?name=309246&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=309246&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641075?name=309246&mode=orpha&region=",
      "regulatory_id": "641075",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=309246&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641075?name=309246&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "N-Acetyl-L-Leucine",
      "substance_url": "/en/drug/substance/591528?name=309246&mode=orpha&region=&status=all",
      "substance_id": "591528",
      "regulatory_url": "/en/drug/regulatory/634594?name=309246&mode=orpha&region=",
      "regulatory_id": "634594",
      "orpha_substance_code": "ORPHA:309152",
      "details": [
        "N-Acetyl-L-Leucine(Medicinal product                        - 11/01/2022)Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
        "N-Acetyl-L-Leucine(Medicinal product                        - 11/01/2022)",
        "(Medicinal product                        - 11/01/2022)",
        "Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/591528?name=309246&mode=orpha&region=&status=all",
          "text": "N-Acetyl-L-Leucine",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/309152",
          "text": "ORPHA:309152 GM2 gangliosidosis",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/634594?name=309246&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US",
        "EU"
      ]
    },
    {
      "name": "Treosulfan",
      "substance_url": "/en/drug/substance/90799?name=309246&mode=orpha&region=&status=all",
      "substance_id": "90799",
      "regulatory_url": "/en/drug/regulatory/136690?name=309246&mode=orpha&region=",
      "regulatory_id": "136690",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Treosulfan(Medicinal product                        - 08/04/2015)Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Treosulfan(Medicinal product                        - 08/04/2015)",
        "(Medicinal product                        - 08/04/2015)",
        "Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/90799?name=309246&mode=orpha&region=&status=all",
          "text": "Treosulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/213500",
          "text": "ORPHA:213500 Rare ovarian cancer",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/136690?name=309246&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "busulfan",
      "substance_url": "/en/drug/substance/46335?name=309246&mode=orpha&region=&status=all",
      "substance_id": "46335",
      "regulatory_url": "/en/drug/regulatory/131973?name=309246&mode=orpha&region=",
      "regulatory_id": "131973",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "busulfan(Medicinal product                        - 21/04/1994)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "busulfan(Medicinal product                        - 21/04/1994)",
        "(Medicinal product                        - 21/04/1994)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/46335?name=309246&mode=orpha&region=&status=all",
          "text": "busulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131973?name=309246&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    }
  ],
  "processing_timestamp": "2025-07-07T06:00:04.283470",
  "run_number": 1,
  "total_drugs_found": 17,
  "search_url": "https://www.orpha.net/en/drug?diseaseName=GM2+gangliosidosis%2C+AB+variant&orphaCode=309246&name=309246&region=&mode=orpha&status=all",
  "search_params": {
    "diseaseName": "GM2 gangliosidosis, AB variant",
    "orphaCode": "309246",
    "name": "309246",
    "region": "",
    "mode": "orpha",
    "status": "all"
  }
}